Aniracetam
Based on 1 publication(s) in Google Scholar
Aniracetam (Ro 13-5057) is an orally active neuroprotective agent, possessing nootropics effects. Aniracetam potentiates the ionotropic quisqualate (iQA) responses in the CA1 region of rat hippocampal slices. Aniracetam also potentiates the excitatory post synaptic potentials (EPSPs) in Schaffer collateral-commissural synapses. Aniracetam can prevents the CO2-induced impairment of acquisition in hypercapnia model rats. Aniracetam can be used to research cerebral dysfunctional disorders.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.94%
- CAS No.: 72432-10-1
- Formule: C12H13NO3
- Masse moléculaire:219.24
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-10933
CX516AMPA Receptor PAM -
HY-B0585
PiracetamiGluR Modulator -
HY-B0007
BaclofenGABABR Agonist -
HY-B0340
NefiracetamCognition-enhancing Agent -
HY-B0589
AtorvastatinHMG-CoA Reductase Inhibitor -
HY-13259
MG-132Proteasome Inhibitor -
HY-17456
OmberacetamDietary Supplement -
HY-16969
Dihexa -
HY-B1715
OxiracetamNootropic Agent -
HY-14840
Phenylpiracetamnicotinic acetylcholine (nACh) receptor Inhibitor -
HY-107482
PicamilonGABA Receptor Agonist -
HY-101528
IDRA 21AMPA Modulator
Publications Citing Use of MedChemExpress (MCE) Aniracetam
MoreVoir tous les produits spécifiques à Isoform iGluR
More
Activité biologique
Description
In Vitro
Aniracetam concentration-dependently counteracts glutsmate-, kainate-, or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced cell death and greatly facilitated neuroprotective response achieved by different concentrations of both quisqualate and trans-1-aminocyclopentane-1, 3-dicarboxylate in primary cultures of cerebellar granule cells[4].
Aniracetam potentiates the mGluR-coupled stimulation of phospholipase C in primary cultures of cerebellar granule cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Aniracetam (10-100 mg/kg; p.o.; single dosage) prevents the CO2-induced impairment of acquisition in rats[2].
Aniracetam (30-300 mg/kg; p.o.; single dosage) increases the percentage of rats showing passive avoidance[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pyramidal neurons from male Wistar rats[1]
-
Dosage:1 mM
-
Administration:30-75 min
-
Result:Potentiated the iQA receptors existing in the brain and produced remarkable facilitation of the native synaptic transmission.
-
Animal Model:Male rats (100-120 g; hypercapnia induced by pure CO2)[2]
-
Dosage:10, 30, 50 and 100 mg/kg
-
Administration:p.o.; single dosage (60 min before hypercapnia)
-
Result:Significantly prevented the CO2-induced impairment of acquisition at 30 and 50 mg/kg.
-
Animal Model:Male rats and male mice (100-120 g and 21-25 g; 0.5 mg/kg Scopolamine-induced transient disruption of the memory of a passive avoidance procedure)[2]
-
Dosage:30, 50, 100 and 300 mg/kg,
-
Administration:p.o.; single dosage
-
Result:Significantly increased the percentage of rats showing passive avoidance 2 h after Scopolamine (HY-N0296) at 50 and 100 mg/kg.
Chemical Information
-
CAS No. 72432-10-1
-
Appearance Solid
-
Masse moléculaire 219.24
-
Formule C12H13NO3
-
Color White to off-white
-
SMILES
O=C(N1CCCC1=O)C2=CC=C(OC)C=C2
-
Synonyms
Ro 13-5057
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Adv
2025 Apr 11;11(15):eads5750. PMID: 40215296
Solvant et solubilité
In Vitro:
DMSO : ≥ 100 mg/mL (456.12 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 0.33 mg/mL (1.51 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (11.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (11.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ito I, et al. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J Physiol. 1990 May;424:533-43. [Content Brief]
[2]. Cumin R, et al. Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology (Berl). 1982;78(2):104-11. [Content Brief]
[3]. Nakamura K. Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. CNS Drug Rev. 2002 Spring;8(1):70-89. [Content Brief]
[4]. Pizzi M, et al. Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells. J Neurochem. 1993 Aug;61(2):683-9. [Content Brief]
[5]. Nakamura K, et al. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. [Content Brief]
[6]. Vaglenova J, et al. Aniracetam reversed learning and memory deficits following prenatal ethanol exposure by modulating functions of synaptic AMPA receptors. Neuropsychopharmacology. 2008 Apr;33(5):1071-83. Epub 2007 Jul 4. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 4.5612 mL | 22.8061 mL | 45.6121 mL | 114.0303 mL |
| DMSO | 5 mM | 0.9122 mL | 4.5612 mL | 9.1224 mL | 22.8061 mL |
| 10 mM | 0.4561 mL | 2.2806 mL | 4.5612 mL | 11.4030 mL | |
| 15 mM | 0.3041 mL | 1.5204 mL | 3.0408 mL | 7.6020 mL | |
| 20 mM | 0.2281 mL | 1.1403 mL | 2.2806 mL | 5.7015 mL | |
| 25 mM | 0.1824 mL | 0.9122 mL | 1.8245 mL | 4.5612 mL | |
| 30 mM | 0.1520 mL | 0.7602 mL | 1.5204 mL | 3.8010 mL | |
| 40 mM | 0.1140 mL | 0.5702 mL | 1.1403 mL | 2.8508 mL | |
| 50 mM | 0.0912 mL | 0.4561 mL | 0.9122 mL | 2.2806 mL | |
| 60 mM | 0.0760 mL | 0.3801 mL | 0.7602 mL | 1.9005 mL | |
| 80 mM | 0.0570 mL | 0.2851 mL | 0.5702 mL | 1.4254 mL | |
| 100 mM | 0.0456 mL | 0.2281 mL | 0.4561 mL | 1.1403 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Aniracetam Related Classifications
HY-10932 Related Classifications
Powered by Bioz